Amplitude Venture Capital launches CAD $200 million fund focused on building world-class precision medicine companies
TORONTO, Ontario, November 6, 2019—Amplitude Venture Capital today announced the launch of a CAD $200 million fund to continue its successful investment strategy of building globally competitive Canadian healthcare companies. The Fund is focused on developing platform companies based on outstanding Canadian precision medicine innovation.
The Fund, which Amplitude co-created with cornerstone investor BDC Capital, has closed on more than 50 per cent of its target signalling strong support for Amplitude’s investment strategy. Founded by the former healthcare investing team at BDC Capital, Amplitude is led by partners Jean-François Pariseau and Dion Madsen.
“Canada boasts an innovation-rich healthcare ecosystem that is home to world-leading academic and research centres,” said Mr. Madsen. “For too long the capital and expertise necessary to scale potentially game-changing ideas into break-out companies has been largely missing in Canada. Our mission is to unite innovators with acceleration capital and our builder vision to create and scale great companies. This is where Amplitude will focus and thrive.”
The Amplitude team managed a CAD $270 million healthcare investment portfolio from 2013-2018 as part of BDC Capital and played a critical role in creating, building, and growing two, billion-dollar Canadian public biotech success stories (Clementia and Zymeworks), and financed two other successful publicly-traded companies (Milestone Pharmaceuticals and Profound Medical).
“The promising track record of Jean-François and Dion in identifying high potential companies and adding genuine value to investments in such a highly specialized sector made BDC Capital’s commitment to anchor Amplitude Ventures an easy decision” said Jérôme Nycz, Executive Vice-President, BDC Capital. “It fits with our overall strategy to build and deploy new, high-performing funds in the Canadian market. We are confident they will increase the velocity of company growth in the Canadian healthcare sector.”
Amplitude’s focus is on precision medicine where world-class Canadian innovators are driving the future of healthcare. The Fund will invest in early-stage and emerging Canadian companies and will also create new companies in collaboration with leading academic institutions.
“We believe we can capture the full potential of Canadian innovation and support and amplify the entrepreneurial vision of founders by providing the focused capital and connections that companies need to take their innovation from idea to IPO,” said Mr. Pariseau. “We are grateful to our LPs for their foundational support. The collective vision of BDC Capital, Fonds de solidarité FTQ, Teralys, Investissement Québec, and Caisse de dépôt et placement du Québec (CDPQ) gives us the platform we need to achieve our goals.”
The Fund’s first investment, in Repare Therapeutics, is now complete and is an excellent example of the kinds of companies Amplitude will support. Repare is developing new, precision oncology drugs that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. The Fund is an investor in both the Series A and the recent USD $83 million Series B round.